Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Rheumatol. doi: /nrrheum

Similar presentations


Presentation on theme: "Nat. Rev. Rheumatol. doi: /nrrheum"— Presentation transcript:

1 Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.83
Figure 2 Estimated serious infection rates among clinical trials of biologics in rheumatoid arthritis Figure 2 | Estimated serious infection rates among clinical trials of biologics in rheumatoid arthritis. The incidence rate of serious infection (number of unique patients with events per 100 patient-years exposure) across clinical trials (including randomized control trials and long-term extension trials) investigating biologics for the treatment of rheumatoid arthritis are displayed using clinical trial data published between 1999 and All trials included patients with moderate to severely active rheumatoid arthritis. JAK, Janus kinase. This figure was adapted with permission obtained from Strand, V. et al. Arthritis Res. Ther. 17, 362 (2015)51, which is published under an open-access licence ( by BioMed Central Ltd. This figure was adapted with permission obtained from Strand, V. et al. Arthritis Res. Ther. 17, 362 (2015)51, which is published under an open-access licence ( by BioMed Central Ltd. Rose-John, S. et al. (2017) The role of IL‑6 in host defence against infections: immunobiology and clinical implications Nat. Rev. Rheumatol. doi: /nrrheum


Download ppt "Nat. Rev. Rheumatol. doi: /nrrheum"

Similar presentations


Ads by Google